10 Celldex Therapeutics Analyst Ratings, Earnings, Dividends and Insider Trades | $CLDX | NASDAQ:CLDX | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Celldex Therapeutics Company Profile (NASDAQ:CLDX) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Celldex Therapeutics (NASDAQ:CLDX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Hold Rating(s), 8 Buy Rating(s)Consensus Rating:Buy (Score: 2.89)Consensus Price Target: $36.29 (43.08% upside) Analysts' Ratings History for Celldex Therapeutics (NASDAQ:CLDX) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare3/4/2014Jefferies GroupBoost Price TargetBuy$29.00 -> $31.00View 3/4/2014Cantor FitzgeraldReiterated RatingBuy$39.00 -> $33.00View 3/4/2014OppenheimerLower Price TargetOutperform$40.00 -> $36.00View 11/7/2013Brean CapitalReiterated RatingBuyView 10/22/2013OppenheimerReiterated RatingBuy$40.00View 10/22/2013Cantor FitzgeraldReiterated RatingBuy$39.00View 10/22/2013Roth CapitalBoost Price TargetBuy$34.00 -> $40.00View 10/7/2013Ned Davis ResearchInitiated CoverageNeutralView 10/2/2013Cantor FitzgeraldReiterated RatingBuy$39.00View 10/2/2013OppenheimerBoost Price Target$40.00View 9/24/2013GuggenheimBoost Price TargetBuy$26.00 -> $34.00View 9/24/2013Cantor FitzgeraldBoost Price TargetBuy$39.00View 9/23/2013Leerink SwannBoost Price TargetOutperform$28.00 -> $45.00View 9/17/2013WedbushReiterated RatingBuy$35.00View 9/17/2013Jefferies GroupBoost Price TargetBuy$25.00 -> $29.00View 9/4/2013WedbushReiterated RatingOutperform$20.00 -> $35.00View 8/7/2013OppenheimerBoost Price Target$16.00 -> $25.00View 8/7/2013Leerink SwannBoost Price Target$18.00 -> $28.00View 8/7/2013Jefferies GroupBoost Price Target$19.00 -> $25.00View 7/24/2013Roth CapitalBoost Price TargetBuy$16.00 -> $34.00View 7/8/2013Cantor FitzgeraldBoost Price TargetBuy$16.00 -> $24.00View 7/3/2013GuggenheimInitiated CoverageBuy$24.00View 6/21/2013OppenheimerReiterated RatingOutperform$14.00 -> $16.00View 6/19/2013Jefferies GroupReiterated RatingBuy$15.00 -> $19.00View 6/12/2013Brean CapitalBoost Price Target$14.00 -> $19.00View 3/8/2013Jefferies GroupBoost Price TargetBuy$9.00 -> $15.00View 3/8/2013Roth CapitalReiterated RatingBuy$16.00View 3/8/2013Cantor FitzgeraldBoost Price TargetBuy$13.00 -> $16.00View 3/6/2013Leerink SwannInitiated CoverageOutperform$18.00View 2/26/2013OppenheimerBoost Price TargetOutperform$10.00 -> $13.00View 1/22/2013Roth CapitalReiterated RatingBuy$16.00View 1/10/2013Cantor FitzgeraldBoost Price TargetBuy$9.00 -> $13.00View 12/10/2012OppenheimerBoost Price Target$10.00View 12/10/2012OppenheimerReiterated RatingOutperformView 12/10/2012Brean CapitalReiterated RatingBuy$14.00View 12/10/2012Jefferies GroupReiterated RatingBuyView 11/2/2012Jefferies GroupBoost Price TargetBuy$6.00 -> $7.00View 10/2/2012OppenheimerBoost Price TargetOutperform$6.00 -> $8.00View 9/14/2012Cantor FitzgeraldBoost Price TargetBuy$7.00 -> $9.00View 6/1/2012ThinkEquityInitiated CoverageBuyView 4/3/2012Cantor FitzgeraldInitiated CoverageBuy$7.00View (Data available from 3/9/2012 forward) Earnings History for Celldex Therapeutics (NASDAQ:CLDX)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare3/3/2014Q413($0.28)($0.27)$0.27 million$0.62 millionViewN/AView 11/5/2013Q313($0.24)($0.29)$0.09 million$1.00 millionViewN/AView 8/6/2013Q2 2013($0.22)($0.24)$1.57 million$0.97 millionViewN/AView 5/2/2013Q1 2013($0.22)($0.23)$2.65 million$2.41 millionViewN/AView 3/7/2013Q4 2012($0.25)($0.27)$2.45 million$3.65 millionViewN/AView 11/1/2012Q312($0.24)($0.25)$2.07 million$3.11 millionViewN/AView 8/10/2012($0.25)($0.23)ViewN/AView 5/3/2012($0.25)($0.27)ViewN/AView 3/7/2012($0.26)($0.29)ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Celldex Therapeutics (NASDAQ:CLDX)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Celldex Therapeutics (NASDAQ:CLDX)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare12/6/2013Avery CatlinCFOSell183,333$24.50$4,491,658.50View 12/6/2013Larry EllbergerDirectorSell17,728$24.50$434,336.00View (Data available from 1/1/2013 forward) About Celldex Therapeutics Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's drug candidates include CDX-110, CDX-011 and CDX-1127. CDX-110, is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). CDX-1127 is a human monoclonal antibody that targets CD27. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology programs, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. Headlines: (3/4) Celldex Therapeutics (CLDX) in Focus: Stock Tumbles 10.1% (3/3) Celldex Reports Fiscal 2013 Business/Financial Results and Outlines 2014 Strategy (3/4) Celldex Therapeutics (CLDX) in Focus: Stock Tumbles 10.1% - Tale of the Tape (2/25) Celldex to Report Fourth Quarter and Fiscal 2013 Business/Financial Results and Host 2014 Strategy Conference Call (3/4) Celldex Posts Narrower-Than-Expected Loss in Q4 (3/4) Celldex Posts Narrower-Than-Expected Loss in Q4 - Analyst Blog (3/3) Celldex Therapeutics Q4 13 Earnings Conference Call At 8:30 AM ET (3/3) Celldex Q4 Loss Per Share Unchanged - Quick Facts Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: CLDX CUSIP: 15117B10 Key Metrics: Previous Close: $26.3750 Day Moving Average: $27.4562200 Day Moving Average: $26.1583 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $2.106BCurrent Quarter EPS Consensus Estimate: $-1.10 EPS Additional Links: View CLDX on Google FinanceView CLDX on Yahoo FinanceView CLDX's Company Profile on ReutersSearch for Celldex Therapeutics Inc. on Google Celldex Therapeutics (NASDAQ:CLDX) Chart for Sunday, March, 9, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.